Loading...
•
Mar 31, 2021
Adaptimmune Q1 2021 Earnings Report
Adaptimmune reported financial results and provided a business update.
Key Takeaways
Adaptimmune reported first quarter financial results, with a revenue of $0.4 million and a net loss of $37.8 million. The company's cash and cash equivalents totaled $32.4 million, and total liquidity reached $317.9 million. Financial guidance confirmed funding into early 2023.
Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO
First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT
Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1
Astellas nominates second target as part of allogeneic co-development and co-commercialization agreement
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into early 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...